SCHEMBL240664

SCHEMBL240664

COc1cccc2nc3ccccc3cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 5/20 0.57
NQO1 P15559 1/20 0.57
TLR8 Q9NR97 1/20 0.56
POLB P06746 5/20 0.55
HPGD P15428 4/20 0.55
LMNA P02545 3/20 0.55
ALDH1A1 P00352 3/20 0.55
GLA P06280 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
KDM4E B2RXH2 2/20 0.55
GAA P10253 1/20 0.55
PTBP1 P26599 1/20 0.55
KMT2A Q03164 1/20 0.55
RCE1 Q9Y256 1/20 0.55
PDE3B Q13370 1/20 0.51
PDE3A Q14432 1/20 0.51
PDGFRB P09619 2/20 0.50
MAPT P10636 2/20 0.50
EGFR P00533 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15271481 0.98 NQO2 (0.56) NQO2NQO1TLR8POLBHPGD
Hydrochloric Acid SCHEMBL32690198 0.96 NQO2 (0.54) NQO2NQO1TLR8POLBHPGD
SCHEMBL27464900 0.86 ALDH1A1 (0.53) NQO2NQO1TLR8POLBHPGD
SCHEMBL5192732 0.85 KMT2A (0.58) NQO2TLR8POLBHPGDLMNA
SCHEMBL10751607 0.81 TLR8 (0.59) TLR8POLBHPGDLMNAALDH1A1
SCHEMBL17423273 0.81 NQO1 (0.52) NQO2NQO1TLR8POLBHPGD
SCHEMBL9755341 0.81 POLB (0.55) NQO2NQO1TLR8POLBHPGD
SCHEMBL6972381 0.80 NQO2 (0.63) NQO2NQO1TLR8POLBLMNA
SCHEMBL14740604 0.80 GLA (0.53) NQO2TLR8POLBHPGDLMNA
SCHEMBL8418578 0.80 TLR8 (0.50) NQO2NQO1TLR8POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250128238-A1 SEPARATION MEDIA CONTAINING DYES DONALDSON COMPANY, INC. 2025-04-24 US disclosed
US-20240124419-A1 SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-04-18 US disclosed
US-20230364084-A1 METHODS FOR PREVENTING OR TREATING CONDITIONS RELATED TO PIKFYVE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-11-16 US disclosed
WO-2023098740-A1 ORGANIC ROOM-TEMPERATURE ELECTROPHOSPHORESCENT MATERIAL, AND PREPARATION METHOD THEREFOR AND ORGANIC ELECTROLUMINESCENT DIODE THEREOF 云南大学 2023-06-08 WO disclosed
US-11607414-B2 Small molecule inhibitors of EGFR and PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-03-21 US disclosed
WO-2022197589-A1 METHODS FOR IN SITU SEQUENCING PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-09-22 WO disclosed
US-11148998-B2 Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-10-19 US disclosed
US-11013817-B2 Nanoparticles for drug delivery to treat bone disease THE CLEVELAND CLINIC FOUNDATION (US) 2021-05-25 US disclosed
US-10968472-B2 Multi-color reporter cells for detecting HIV-1 WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2021-04-06 US disclosed
US-20210023085-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2021-01-28 US disclosed
EP-1974053-A1 ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE Keygene N.V. (NL) 2008-10-01 EP disclosed
US-20080089896-A1 Bivalent SMAC mimetics and the uses thereof REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2008-04-17 US disclosed
WO-2007136840-A2 NUCLEIC ACID LIBRARY DESIGN AND ASSEMBLY CODON DEVICES, INC. (US) 2007-11-29 WO disclosed
WO-2007136834-A2 COMBINED EXTENSION AND LIGATION FOR NUCLEIC ACID ASSEMBLY CODON DEVICES, INC. (US) 2007-11-29 WO disclosed
WO-2007087336-A2 METHODS FOR DETECTING NUCLEIC ACIDS USING MULTIPLE SIGNALS QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) 2007-08-02 WO disclosed
US-20070172836-A1 Methods for detecting nucleic acids using multiple signals QUEST DIAGNOSTICS INVESTMENTS INCORPORATED 2007-07-26 US disclosed
WO-2007073149-A1 ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE KEYGENE N.V. (NL) 2007-06-28 WO disclosed
WO-2007073154-A1 ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE KEYGENE N.V. (NL) 2007-06-28 WO disclosed
WO-2006099160-A2 BIOLUMINESCENCE RESONANCE ENERGY TRANSFER (BRET) SYSTEMS AND METHODS OF USE THEREOF STANFORD UNIVERSITY (US) 2006-09-21 WO disclosed
CN-1354799-A Enzymatic methods for measuring lysophospholipids and phospholipids and correlation with disease ATAIRGIN BIOTECHNOLOGIES INC (US) 2002-06-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11607414-B2 Small molecule inhibitors of EGFR and PI3K EGFR, ERBB2, ERBB3 NQO2 541/4885NQO1 2627/4885TLR8 2634/4885
US-11148998-B2 Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof RARB, RXRB, RXRA NQO2 559/4885NQO1 988/4885TLR8 3749/4885
US-20240124419-A1 SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF HSPA5, HSPA2, PSMG3 NQO2 2626/4885NQO1 2738/4885TLR8 2855/4885
US-20210023085-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K EGFR, ERBB2, ERBB3 NQO2 541/4885NQO1 2627/4885TLR8 2634/4885
US-20080089896-A1 Bivalent SMAC mimetics and the uses thereof BID, BAD, BIRC2 NQO2 2841/4885NQO1 3766/4885TLR8 4189/4885
US-20230364084-A1 METHODS FOR PREVENTING OR TREATING CONDITIONS RELATED TO PIKFYVE ACTIVITY PIKFYVE, PPME1, MTMR1 NQO2 3836/4885NQO1 3763/4885TLR8 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.